Published in Ann Oncol on December 28, 2015
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol (2016) 0.95
Advances in Cancer Immunotherapy in Solid Tumors. Cancers (Basel) (2016) 0.85
Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report. Front Oncol (2016) 0.82
Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci (2017) 0.82
Genomic Approaches to Understanding Response and Resistance to Immunotherapy. Clin Cancer Res (2016) 0.81
Practical ImmunoPET radiotracer design considerations for human immune checkpoint imaging. J Nucl Med (2016) 0.80
Recent Advances in Immunotherapy in Metastatic NSCLC. Front Oncol (2016) 0.79
Pembrolizumab (Keytruda). Hum Vaccin Immunother (2016) 0.78
Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments. Oncotarget (2016) 0.75
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. World J Clin Oncol (2017) 0.75
Nivolumab-associated acute glomerulonephritis: a case report and literature review. BMC Nephrol (2016) 0.75
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. Oncologist (2016) 0.75
Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations. P T (2017) 0.75
Pharmacogenomics of off-target adverse drug reactions. Br J Clin Pharmacol (2017) 0.75
Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab. ESMO Open (2017) 0.75
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. Br J Cancer (2017) 0.75
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. Curr Oncol Rep (2017) 0.75